Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR029 in R/R B-cell NHL
NCT03355859Phase 1Unknown
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relmacabtagene autoleucel in B-cell non-Hodgkin lymphoma. Primary endpoints: Treatment-related adverse events at 2 years, Dose-limiting toxicities at 28 days and 1 more. Status: unknown.
02
Drugs
relmacabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03355859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355859.